IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial

IN8BIO, INC.

2023-Q1 EPS reported -$0.30

Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.
INB-100 Phase 1: 100% complete remissions in 7 evaluable leukemia patients; all alive; selected RP2D.
FDA orphan drug designation for INB-400 and INB-410 for malignant gliomas, including GBM.
INB-200 Phase 1 data selected for oral abstract at ASCO 2023; new preclinical data in ovarian cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IN8BIO, INC. reported first quarter ended March 31, 2023 results: net income $7.5 million, EPS $0.30 per basic and diluted common share.

Period: first quarter ended March 31, 2023
Net income: $7.5 million
EPS: $0.30 per basic and diluted common share
Result: reported results

Exact text from the filing

The Company reported a net loss of $7.5 million, or $0.30 per basic and diluted common share, for the three months ended March 31, 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-021505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.